Cargando…

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of genotype, relapses as aggressive recurrent disease. Sensitization of GBM cells to chemo-radiation is expected to extend surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Shiv K., Smith, Emily J., Mladek, Ann C., Tian, Shulan, Decker, Paul A., Kizilbash, Sani H., Kitange, Gaspar J., Sarkaria, Jann N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349736/ https://www.ncbi.nlm.nih.gov/pubmed/30723695 http://dx.doi.org/10.3389/fonc.2018.00670

Ejemplares similares

TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
por: Kitange, Gaspar, et al.
Publicado: (2023)

Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
por: Gupta, Shiv K., et al.
Publicado: (2019)

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
por: Harder, Bryan G., et al.
Publicado: (2019)

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022)

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells
por: Nagel, Zachary D., et al.
Publicado: (2019)

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
por: Toma, Monika, et al.
Publicado: (2018)

TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS
por: Kizilbash, Sani, et al.
Publicado: (2023)

Quantifying Glioblastoma Drug Response Dynamics Incorporating Treatment Sensitivity and Blood Brain Barrier Penetrance From Experimental Data
por: Massey, Susan Christine, et al.
Publicado: (2020)

Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme
por: Tivnan, Amanda, et al.
Publicado: (2015)

Main Manuscript for Cell migration simulator-based biomarkers for glioblastoma
por: Hou, Jay, et al.
Publicado: (2023)

Protein kinase C(ι) and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities
por: Kenchappa, Rajappa S., et al.
Publicado: (2021)

Perivascular Stromal Cells Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model
por: Ngo, Mai T., et al.
Publicado: (2022)

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation
por: Pellot Ortiz, Karolina I., et al.
Publicado: (2023)

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models
por: Conage-Pough, Jason E, et al.
Publicado: (2023)

PARP inhibitors protect against sex- and AAG-dependent alkylation-induced neural degeneration
por: Allocca, Mariacarmela, et al.
Publicado: (2017)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
por: Randall, Elizabeth C., et al.
Publicado: (2018)

Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
por: DeCordova, Syreeta, et al.
Publicado: (2020)

PARP-1 protein expression in glioblastoma multiforme
por: Galia, A., et al.
Publicado: (2012)

Radioiodinated PARP1 tracers for glioblastoma imaging
por: Salinas, Beatriz, et al.
Publicado: (2015)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
por: Ducray, François, et al.
Publicado: (2010)

Aag DNA Glycosylase Promotes Alkylation-Induced Tissue Damage Mediated by Parp1
por: Calvo, Jennifer A., et al.
Publicado: (2013)

PARP-1 Modulation of mTOR Signaling in Response to a DNA Alkylating Agent
por: Éthier, Chantal, et al.
Publicado: (2012)

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion
por: Jermakowicz, Anna M., et al.
Publicado: (2021)

Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers
por: Rabah, Nadin, et al.
Publicado: (2023)

Topotactic transformation of homogeneous phosphotungastomolybdic acid materials to heterogeneous solid acid catalyst for carbohydrate conversion to alkyl methylfurfural and alkyl levulinate
por: Gupta, Dinesh, et al.
Publicado: (2020)

Parp1 protects against Aag-dependent alkylation-induced nephrotoxicity in a sex-dependent manner
por: Calvo, Jennifer A., et al.
Publicado: (2016)

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
por: Karpel-Massler, Georg, et al.
Publicado: (2014)

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma
por: Gupta, Kshama, et al.
Publicado: (2020)

Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma
por: Hu, Leland S., et al.
Publicado: (2015)

Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit
por: Sage, William, et al.
Publicado: (2017)

LPA signaling is regulated through the primary cilium: a novel target in glioblastoma
por: Loskutov, Yuriy V., et al.
Publicado: (2018)

Network Modeling Identifies Patient-specific Pathways in Glioblastoma
por: Tuncbag, Nurcan, et al.
Publicado: (2016)

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors
por: Griffith, Jessica I., et al.
Publicado: (2020)

Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model
por: Chen, Jee-Wei Emily, et al.
Publicado: (2020)

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling
por: Oliva, Claudia R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pvmssjro2c75amc5rs9ndp65go